It will be some time before any of them get approved as I understand, so I have focused more on the short term issues. Most of their stuff is phase II right now, which costs a lot less than phase III (Or that is my current understanding), so I think I see more rally potential, and less fund raising risk right now, than at any other time, low future costs 1-2 years, and lots cash on hand.
The phase III studies are very costly, but are critical to final FDA approval, they have the huge $50 versus versus .05/share one day news risk/reward status from what I have seen, on one trick pony companies, ones like XTLBY which dropped 99% in price in about 1 hour when news of an FDA problem with the phase III hit the wires.
I see much less risk on CYTR right now as I bought it first at .36/share (or about that) back at the bottom of the market crash in March 09, and I held those and added at $1.20, and I am close to adding right now. CYTR has smart management. They raised cash just before the market collapsed in 08, and bought RXII for near nothing, and save it from the scrap heap, then made a killing selling of most it last year and early this year. They also have actually had a track record of making a successful drug deal that generated income at least once before in 07-09 period. Unlike many of the other endless black holes in the biotech field.
I think this is a solid $3 stock in a good bull market, as of today. More good news like the recent block buster cancer cure success stories from the last 2 weeks, for those walking dead patients that had been written off as hopeless, that are now cured according to the 6 month reports of no return of the leukemia, and this stock should soar soon! Especially since that same drug, which they hold the rights to, has good potential for billion dollar cancers, which they plan to explore soon as well.
The current one, with the high total cure of cancer patients that had been written off as walking dead (all the approved drugs and treatments had failed twice, on these patients already!!!), was a an orphan drug (or similar??) fast track back door to get the drug proven, and to show the world its real potential, and safety, but there is not a lot of profit in orphan drugs, and little volume in that particular cancer (which is why I think it got the fast track trials for patients who had no hope left).
Long story short, I think the CYTR crew knows what it is doing, good drugs, with great potential, and some shrewd cash managers on board. They did quite well the last 2 years, in spite of the markets collapse.
Their is a ton of great detail in their prospectus, if you take time to read it. I am a little lucky in that my brother is a retired MD, and he was one of the inventors of the first chemotherapy drug at MD Anderson, and with my own biochemical engineering gives me an edge on understanding the drugs/biochemistry.
I have high hopes for this one, and it is currently one of my largest holdings. LOL, and if my last name was Buffet or Gates, that might be worth something, LOL!!!
Market Data 
Markets 
AI
